PEMBROSARC, NCT02406781: Combination of MK3475 and Metronomic Cyclophosphamide in Patients With Advanced Sarcomas : Multicentre Phase II Trial |
|
|
| Active, not recruiting | 2 | 227 | Europe | Combination of MK3475 with Metronomic CP, Pembrolizumab, Endoxan, Combination of MK3475 with Metronomic CP and G100, Pembrolizumab, Endoxan, GLA-SE (glucopyranosyl lipid adjuvant-stable emulsion). | Institut BergoniƩ, Merck Sharp & Dohme LLC, Ministry of Health, France, Immune Design | Sarcoma | 11/20 | 08/21 | | |